Rankings
▼
Calendar
BIIB Q4 2024 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
Q4 2024 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$2.5B
+2.9% YoY
Gross Profit
$1.9B
76.2% margin
Operating Income
$509M
20.7% margin
Net Income
$267M
10.9% margin
EPS (Diluted)
$1.83
QoQ Revenue Growth
-0.5%
Cash Flow
Operating Cash Flow
$761M
Free Cash Flow
$695M
Stock-Based Comp.
$75M
Balance Sheet
Total Assets
$28.0B
Total Liabilities
$11.3B
Stockholders' Equity
$16.7B
Cash & Equivalents
$2.4B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.5B
$2.4B
+2.9%
Gross Profit
$1.9B
$1.8B
+5.8%
Operating Income
$509M
$512M
-0.7%
Net Income
$267M
$250M
+6.8%
Revenue Segments
MS Product Revenues
$1.1B
42%
SPINRAZA
$421M
17%
TYSABRI product
$415M
16%
Fumarate
$404M
16%
Interferon
$236M
9%
Geographic Segments
Non-US
$1.0B
55%
UNITED STATES
$832M
45%
← FY 2024
All Quarters
Q1 2025 →